| Code | CSB-RA859530MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Rilogrotug, designed for research targeting Growth Differentiation Factor 15 (GDF15). GDF15 is a stress-responsive cytokine and member of the transforming growth factor-beta superfamily that plays critical roles in cellular stress responses, metabolism, and inflammation. Under physiological conditions, GDF15 is expressed at low levels, but its expression increases dramatically in response to tissue injury, inflammation, and various pathological states. Elevated GDF15 levels are associated with cancer progression, cachexia, cardiovascular disease, and metabolic disorders, making it an important biomarker and therapeutic target.
Rilogrotug represents a therapeutic antibody developed to neutralize GDF15 activity, originally investigated for the treatment of cancer-associated cachexia and anorexia. This biosimilar provides researchers with a valuable tool for investigating GDF15-mediated signaling pathways, exploring its role in disease pathogenesis, and evaluating potential therapeutic interventions. The antibody enables studies examining GDF15's involvement in tumor microenvironments, metabolic regulation, and stress response mechanisms across various experimental models.
There are currently no reviews for this product.